Sanjay Gandhi to Heptanoic Acids
This is a "connection" page, showing publications Sanjay Gandhi has written about Heptanoic Acids.
Connection Strength
1.542
-
Folse H, Sternhufvud C, Andy Schuetz C, Rengarajan B, Gandhi S. Impact of switching treatment from rosuvastatin to atorvastatin on rates of cardiovascular events. Clin Ther. 2014 Jan 01; 36(1):58-69.
Score: 0.462
-
Schuetz CA, van Herick A, Alperin P, Peskin B, Hsia J, Gandhi S. Comparing the effectiveness of rosuvastatin and atorvastatin in preventing cardiovascular outcomes: estimates using the Archimedes model. J Med Econ. 2012; 15(6):1118-29.
Score: 0.417
-
Costa-Scharplatz M, Ramanathan K, Frial T, Beamer B, Gandhi S. Cost-effectiveness analysis of rosuvastatin versus atorvastatin, simvastatin, and pravastatin from a Canadian health system perspective. Clin Ther. 2008 Jul; 30(7):1345-57.
Score: 0.315
-
Fox KM, Gandhi SK, Ohsfeldt RL, Davidson MH. Comparison of low-density lipoprotein cholesterol reduction after switching patients on other statins to rosuvastatin or simvastatin in a real-world clinical practice setting. Am J Manag Care. 2007 Dec; 13 Suppl 10:S270-5.
Score: 0.076
-
Insull W, Ghali JK, Hassman DR, Y As JW, Gandhi SK, Miller E. Achieving low-density lipoprotein cholesterol goals in high-risk patients in managed care: comparison of rosuvastatin, atorvastatin, and simvastatin in the SOLAR trial. Mayo Clin Proc. 2007 May; 82(5):543-50.
Score: 0.073
-
Bullano MF, Kamat S, Wertz DA, Borok GM, Gandhi SK, McDonough KL, Willey VJ. Effectiveness of rosuvastatin versus atorvastatin in reducing lipid levels and achieving low-density-lipoprotein cholesterol goals in a usual care setting. Am J Health Syst Pharm. 2007 Feb 01; 64(3):276-84.
Score: 0.072
-
Ohsfeldt RL, Gandhi SK, Fox KM, Stacy TA, McKenney JM. Effectiveness and cost-effectiveness of rosuvastatin, atorvastatin, and simvastatin among high-risk patients in usual clinical practice. Am J Manag Care. 2006 Nov; 12(15 Suppl):S412-23.
Score: 0.070
-
Ohsfeldt RL, Gandhi SK, Fox KM, McKenney JM. Statin cost-effectiveness comparisons using real-world effectiveness data: formulary implications. Value Health. 2008 Dec; 11(7):1061-9.
Score: 0.020
-
Harley CR, Gandhi SK, Heien H, McDonough K, Nelson SP. Lipid levels and low-density lipoprotein cholesterol goal attainment in diabetic patients: rosuvastatin compared with other statins in usual care. Expert Opin Pharmacother. 2008 Apr; 9(5):669-76.
Score: 0.019
-
Harley CR, Gandhi S, Blasetto J, Heien H, Sasane R, Nelson SP. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice. Am J Geriatr Pharmacother. 2007 Sep; 5(3):185-94.
Score: 0.019